Agenus to Participate at Jefferies Healthcare Conference
May 25, 2022 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers...
Agenus Announces Late-Breaking Oral Presentation at ESMO-GI and Strategies to Advance Botensilimab
May 24, 2022 08:30 ET
|
Agenus Inc.
Data to be Presented in Heavily Pretreated MSS-CRCSpeed and Innovation Core to Development StrategyReduction of 20% in 2022 Operating Costs LEXINGTON, Mass., May 24, 2022 (GLOBE NEWSWIRE) --...
Agenus Corporate Update and First Quarter 2022 Financial Report
May 10, 2022 08:00 ET
|
Agenus Inc.
Botensilimab data to be presented and Phase 2 trials to launch.AGEN1571 (ILT2) clinical trials to commence and data presented at AACR.AGEN2373 progressing in the clinic and Gilead milestone payment...
Agenus to Provide Corporate Update and First Quarter 2022 Financial Report
April 26, 2022 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to...
Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance
April 08, 2022 13:00 ET
|
Agenus Inc.
First data presentation on AGEN1571 shows strong adaptive and innate immune responsesPreclinical data indicate superior performance to the only clinical-stage competitorMonotherapy activity and broad...
Agenus’ CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead
April 05, 2022 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers...
Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™
March 07, 2022 07:00 ET
|
Agenus Inc.
The parties have entered into a collaboration agreement to develop Targovax´s TG mutant KRAS cancer vaccines in combination with Agenus´s QS-21 STIMULON adjuvant technologyThe agreement may be...
Agenus Corporate Update and Fourth Quarter & Full Year 2021 Financial Report
March 01, 2022 08:00 ET
|
Agenus Inc.
Botensilimab (Fc-enhanced) is the first anti-CTLA-4 antibody to demonstrate clinical responses across 9 cold, treatment-resistant cancers; Phase II studies planned in melanoma, MSS-colorectal, and...
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2021 Financial Report
February 15, 2022 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to...
Agenus to Participate at Upcoming Investor Conferences
January 05, 2022 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to...